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Abstract
Background: Increasing evidence implicates the critical roles of epigenetic regulation in cancer. Very recent reports indicate
that global gene silencing in cancer is associated with specific epigenetic modifications. However, the relationship between
epigenetic switches and more dynamic patterns of gene activation and repression has remained largely unknown.
Methodology/Principal Findings: Genome-wide profiling of the trimethylation of histone H3 lysine 4 (H3K4me3) and lysine
27 (H3K27me3) was performed using chromatin immunoprecipitation coupled with whole genome promoter microarray
(ChIP-chip) techniques. Comparison of the ChIP-chip data and microarray gene expression data revealed that loss and/or
gain of H3K4me3 and/or H3K27me3 were strongly associated with differential gene expression, including microRNA
expression, between prostate cancer and primary cells. The most common switches were gain or loss of H3K27me3 coupled
with low effect on gene expression. The least prevalent switches were between H3K4me3 and H3K27me3 coupled with
much higher fractions of activated and silenced genes. Promoter patterns of H3K4me3 and H3K27me3 corresponded
strongly with coordinated expression changes of regulatory gene modules, such as HOX and microRNA genes, and
structural gene modules, such as desmosome and gap junction genes. A number of epigenetically switched oncogenes and
tumor suppressor genes were found overexpressed and underexpressed accordingly in prostate cancer cells.
Conclusions/Significance: This work offers a dynamic picture of epigenetic switches in carcinogenesis and contributes to an
overall understanding of coordinated regulation of gene expression in cancer. Our data indicate an H3K4me3/H3K27me3
epigenetic signature of prostate carcinogenesis.
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Introduction
Epigenetics refers to heritable, but potentially reversible,
alternated phenotypic states without difference in genotype. The
proteins that mediate epigenetic changes are involved in dynamic
transcriptional control of gene expression and are encoded by
more than 100 genes including DNA methyltransferases (DNMTs),
histone acetyltransferases (HATs), histone deacetylases (HDACs),
histone methyltransferases (HMTs), histone demethylases
(HDMTs) and chromatin remodelling enzymes [1]. EZH2
(Enhancer of Zeste homolog 2), a known core component of the
polycomb repressive complex 2 (PRC2), is one of the best
characterized HMTs, and can trimethylate the histone H3 lysine
27 (H3K27) and thereby repress gene transcription [2]. Previous
work has shown that EZH2 was significantly upregulated and
associated with high proliferation rate and aggressive tumor
subgroups in prostate cancer [3]. However, the targets and output
of epigenetic regulation in prostate cancer are still not completely
understood.
Genome-wide profiling of the H3K27me3 modification in
prostate cancer has been carried out by a few groups. Yu et al. have
analyzed H3K27me3 location and suggested a polycomb
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4687repression signature in metastatic prostate cancer [4]. It would be
informative if H3K27me3 locations were also mapped in benign
tissues to show the cancer specificity of the signature. Very
recently, H3K27me3 modifications were mapped in both prostate
cancer and normal cell lines and a set of genes silenced by EZH2-
mediated H3K27 trimethylation specifically in prostate cancer was
identified [5]. Both works shed light on the silencing function of
EZH2 in prostate cancer, but little is known about epigenetic gene
activation in prostate carcinogenesis.
To systematically examine the role of epigenetic regulation in
prostate cancer, we have screened dysregulated genes in prostate
cancer tissues and cell lines using microarray techniques. We
found that the most significantly changed epigenetic regulators in
both prostate cancer tissues and cell lines were EZH2, SMYD3 and
DNMT3A, which function as H3K27 trimethyltransferase, H3K4
di/tri-methyltransferase [6] and DNA methyltransferase [7],
respectively. Trimethylation of H3K27 (H3K27me3) and tri-
methylation of H3K4 (H3K4me3) are associated with repression
and activation of gene transcription, respectively [2,6]. To
examine the hypothesis that dysregulated genes in prostate cancer
contain a distinct pattern of H3K4me3 and H3K27me3, ChIP-
chip analysis was performed for genome-wide profiling of
H3K4me3 and H3K27me3 modification patterns in both prostate
primary cells and cancer cells. Comparison of the epigenetic
switches and gene expression switches between normal primary
and cancer cells indicated an H3K4me3/H3K27me3 epigenetic
signature in prostate carcinogenesis.
Results
Dysregulated Epigenetic Genes in Prostate Cancer
To analyze the dysregulated epigenetic genes in prostate cancer,
we screened the microarray gene expression data of prostate
cancer and benign tissues as previously published [8,9] and
created a subset of the summarized epigenetic genes, and ranked
them according to fold change between prostate benign and
cancer tissues. The top three (fold change.1.5, p-value,3E-10)
changed epigenetic enzymes were EZH2, SMYD3 and DNMT3A
(Figure 1A, Table S1 in the Supplemental Data available online).
All of them were overexpressed in prostate cancer. EZH2 is a
known H3K27 trimethyltransferase, catalyzing H3K27me3, a
transcriptional repressive mark [2]. SMYD3 is an HMTase
specific for both di- and trimethylation of H3K4, catalyzing
H3K4me2/me3, a transcriptional activating mark [6]. DNMT3A
is a de novo DNA methyltransferase repressing gene transcription
[7]. To our knowledge, this is the first report of overexpression of
both SMYD3 and DNMT3A in prostate cancer tissues. Very
interestingly, five of the top eight changed epigenetic genes were
involved in histone H3 lysine methylation (Figure 1B).
We also did genome-wide profiling of the expression patterns of
prostate cell lines and screened the changed epigenetic genes
between them using the same strategy as in prostate tissues. PC3
cells and EP156T cells were used as prostate cancer and primary
cells, respectively. The PC3 cell line was initiated from a bone
metastasis of a prostatic adenocarcinoma. The EP156T cell line
was established from benign prostate tissue and was characterized
as an immortalized primary prostate epithelial cell line [10]. As
shown in Figure 1C, the top eight differentially expressed
epigenetic genes in prostate cancer have the same expression
patterns as in PC3 cells compared with EP156T cells. The high
consistency of the most significantly changed epigenetic genes
between prostate tissues and cell lines suggested that main
epigenetic regulations in prostate carcinogenesis could be
mediated by histone H3 lysine methylations.
Genome-wide Analysis of H3K4me3 and H3K27me3
Modifications in Prostate Cells
It was very interesting to identify EZH2 and SMYD3 as the most
significantly changed and overexpressed histone modifiers in
prostate cancer, since the two modifications are antagonistic and
Figure 1. Microarray-based Screening of Changed Epigenetic Genes in Prostate Cancer. A. The top significantly changed epigenetic
genes in prostate cancer were overexpressed EZH2, SMYD3 and DNMT3A. B. The most significantly changed epigenetic genes in prostate cancer were
involved in histone 3 lysine methylation. C. Changed epigenetic genes in prostate cancer tissues have the same changed patterns as the prostate
cancer cell line PC3 compared with primary prostate EP156T cells. Asterisks indicate gene expressions with fold change values.1.5 and p-values,3E-
10 in prostate cancer tissues compared with benign tissues.
doi:10.1371/journal.pone.0004687.g001
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gene transcription, respectively. To examine the epigenetic
signature of H27K4me3 and H3K4me3 in prostate cancer,
chromatin immunoprecipitation (ChIP) coupled with promoter
microarray (chip) analysis was performed for genome-wide
profiling of H3K4me3 and H3K27me3 modification patterns.
The prostate cancer cell line PC3 and primary epithelial EP156T
cells were selected for profiling because the changed epigenetic
gene expression patterns between them were similar to prostate
cancer vs benign tissues in vivo (Figure 1). DNA fragments pulled
down by ChIP-grade antibodies against H3K4me3 and
H3K27me3 were hybridized to Agilent human promoter micro-
arrays which comprise ,244,000 60-mer oligonucleotide probes
spaced every ,195 bp across promoter regions including
25.5 Kb upstream and +2.5 Kb downstream of identified
transcriptional start sites (TSS). The probes covered ,17,000 of
the best-defined human transcripts represented as RefSeq.
More H3K27me3 peaks (36922) than H3K4me3 peaks (28837)
were identified in PC3 cells, while more H3K4me3 peaks (41211)
than H3K27me3 peaks (34480) were found in EP156T cells (Table
S2, S3, S4, and S5). A similar higher abundance of H3K27me3
marks in PC3 compared to normal cells was very recently reported
by another group [11], suggesting that the polycomb system is
globally more active in PC3 cells. These peaks can be divided into
6 categories according to probe location in relation to the nearby
TSS (Figure 2A). In both cell lines, most H3K4me3 peaks
accumulated inside RefSeq genes, while most H3K27me3 peaks
mapped to promoter regions (Figure 2A).
In PC3 cells the identified H3K4me3 and H3K27me3 peaks
corresponded to 8415 and 5508 genes, respectively. The numbers
were 9228 and 4972 genes in EP156T cells, respectively.
Calculations of peaks per gene suggested more extensive
H3K27me3 than H3K4me3 modifications of both cell lines,
especially in PC3 cells (6.7 peaks/gene vs 3.4 peaks/gene), and
comparable to human embryonic stem (ES) cells [12,13]. To
confirm the histone H3 trimethylations identified by ChIP-chip,
ChIP-qPCR was used to detect selected genes in both cell lines
with high correlation between the two methods (Figure S1). We
Figure 2. Whole-Genome Distributions of H3K4me3 and H3K27me3 in Prostate Cells. A. Distribution of H3K4me3 and H3K27me3 peaks
related to transcription start site (TSS) and the following subregions: PROMOTER (25.5 Kb upstream from the TSS), DIVERGENT PROMOTER (upstream
from two genes that are transcribed in opposite directions), INSIDE (inside a gene), DOWNSTREAM (+2.5 Kb beyond the end of gene), NONE (no
genomic features upstream or downstream of the probe) and UNKNOWN (no known information regarding presence of genomic features upstream
or downstream of the probe). B. Distribution of H3K4me3 and H3K27me3 peaks in chromosomes, asterisks show chromosomes which differ more
than twofold in peak densities of H3K4me3 and H3K27me3. C. Percentages of H3K4me3 only, H3K27me3 only, bivalent H3K4&K27me3 and Neither
marked genes in PC3 and EP156T cells. D. Numbers and percentages of genes that are different and in common between PC3 and EP156T within the
different categories of H3K4me3 and H3K27me3 mark combinations.
doi:10.1371/journal.pone.0004687.g002
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recently [5] to our promoter array data, and found that 158 genes
have the same gene symbols in our Agilent file. About 70% (111
out of 158) overlapped with H3K27me3 marked genes in our data,
supporting reliable data on both sides.
To compare peak distribution in individual chromosomes, we
normalized the chromosome peak densities by gene numbers in
each chromosome. As shown in Figure 2B, most chromosomes
except Chr Y have similar peak densities of both H3K4me3 and
H3K27me3 in EP156T cells, while it is quite different in PC3 cells.
Many chromosomes have much higher (more than two fold) peak
densities of H3K27me3 than of H3K4me3, including Chr 4, 6, 8,
Y and especially Chr X, while Chr 15 has many more H3K4me3
peaks. It is very interesting that most genes (84%, 439/572) of the
X chromosome of PC3 cells were modified by H3K27me3 (Table
S6), since it was reported that global enrichment of H3K27me3 in
the X chromosome was involved in early steps of X-chromosome
inactivation in ES cells [14,15]. The Y chromosome is also
interesting because it has many more H3K4me3 peaks in EP156T
in contrast to more H3K27me3 in PC3 cells.
Bivalent H3K4me3 and H3K27me3 Modified Genes were
Strikingly Different in Prostate Primary and Cancer Cells
Bernstein et al. surveyed H3K4me3 and H3K27me3 in 60.3 Mb
of murine ES cell genome and uncovered ‘‘bivalent domains’’ that
show promoters harboring both H3K4me3 and H3K27me3
modified sites [12]. The bivalent modification was proposed to
keep the key developmental genes in poised states for later
activation. However, recent genome-wide mapping of histone
modifications indicates that bivalent-modified domains are not
only unique to ES cells but also can be found in differentiated cells
such as T cells and mouse embryonic fibroblasts (MEFs)
[16,17,18].
According to the H3K4me3 and H3K27me3 modification
patterns, all genes in PC3 and EP156T cells were divided into four
categories: 1) H3K4me3 only, 2) H3K27me3 only, 3) bivalent
H3K4&K27me3 and 4) neither H3K4me3 nor H3K27me3
(Neither) (Table S7, 8). The distributions were quite similar in
both cells (Figure 2C): around one-third of genes were associated
with H3K4me3 only, one-sixth of genes with H3K27me3 only and
one-sixth with bivalent H3K4&K27me3. Around half of all
H3K27me3 modified genes were also H3K4me3 modified in both
PC3 and EP156T cells, showing that bivalent H3K4me3 and
H3K27me3 can be found in both prostate somatic cells and cancer
cells. However, a comparison of genes within each group revealed
striking differences between EP156T cells and PC3 cells. The
majority (71.6%) of bivalently H3K4&K27me3 and H3K27me3
only (69.3%) marked genes differed between EP156T and PC3,
while only minor proportions of genes were different within the
H3K4me3 and Neither groups (Figure 2D). This suggested that
epigenetic reprogramming of bivalent H3K4&K27me3 and
H3K27me3 marks happened from primary prostate cells to
cancer cells, but the extent of the two modifications was kept at
similar levels in both cells.
Correlation between H3K4me3 and H3K27me3
modifications and gene expression
The mRNA expression levels of H3K4me3 and H3K27me3
marked genes in PC3 and EP156T cells were analyzed based on
microarray data. Gene expression levels were compared between
four groups. As shown in Figure 3A, very consistent relationships
were found in both cell lines. H3K4me3 only genes were highest
expressed, followed by the bivalent H3K4&K27me3 and Neither
genes. The least expressed genes were associated with H3K27me3
only. This suggests that loss of H3K4me3 (change to Neither or
H3K27me3 only) or gain of H3K27me3 (change to bivalent
H3K4&K27me3 or H3K27me3 only) will repress gene expression.
Loss of H3K27me3 (change to Neither or H3K4me3 only) or gain
of H3K4me3 (change to bivalent H3K4&K27me3 or H3K4me3
only) will enhance gene expression. The rank of gene expression
levels among these four groups in prostate cells shows close
agreement with ES cells [13,17,19]. However, the bivalently
marked genes were rather active and only moderately less
expressed than H3K4me3 only marked genes in both EP156T
and PC3 cells (Figure 3A).
To investigate the relationship between changed H3K4me3 and
H3K27me3 modification patterns and differentially expressed
genes in PC3 cells compared with EP156T cells, three subsets were
created based on epigenetic changes of H3K4me3 and
H3K27me3: 1) repressed: gene loss of H3K4me3 and/or gain of
H3K27me3; 2) activated: loss of H3K27me3 and/or gain of
H3K4me3; 3) unchanged (Figure 3B). There were many more
repressed genes (4134) than activated genes (2932) according this
standard (Table S9). Comparing upregulated and downregulated
genes in PC3 cells (Table S10) with the three subsets, we found
that upregulated genes were enriched significantly in the activated
subset, while downregulated genes were enriched significantly in
the repressed subset (Chi-square test, p,0.01) (Figure 3B). Our
data indicate that loss or gain of H3K4me3 and H3K27me3 is
strongly associated with differential gene expression between
prostate cancer cells and primary cells.
We further asked which epigenetic pattern changes that mainly
contribute to the up- and downregulation from primary to cancer
prostate cells. There are 6 combinations of both repressive and
activating changes of H3K4me3 and H3K27me3 modifications.
For repressive changes: H3K4me3 to H3K27me3 or
H3K4&K27me3 or Neither; H3K4&K27me3 to Neither or
H3K27me3; Neither to H3K27me3; for activating changes:
H3K27me3 to H3K4me3 or H3K4&K27me3 or Neither; Neither
to H3K4&K27me3 or H3K4me3; H3K4&K27me3 to H3K4me3.
A comparison of gene expression among these combinations
showed that the highest enrichment of differentially expressed
genes was associated with the switches between H3K27me3 and
H3K4me3. Up to 46.6% of H3K27me3 to H3K4me3 genes were
upregulated in PC3 cells with extremely low overlap with
downregulated genes (0.37%), and 36.9% of H3K4me3 to
H3K27me3 genes were downregulated in PC3 cells with
extremely low overlap with upregulated genes (1.8%) (Chi-square
test, p,0.01), while the lowest enrichment of differentially
expressed genes belonged to the switches between H3K27me3
only & Neither and H3K4me3 only and H3K4&K27me3 (from
8% to 13%) (Figure 3C). This is consistent with the notion that
both H3K27me3 only and Neither are transcriptional silencing
marks, and H3K4me3 only and H3K4&K27me3 are both
activating marks. These findings indicate that the switches
between H3K27me3 only and H3K4me3 only play the most
important role in differential gene expression between prostate
normal and cancer cells.
A very interesting inverse relationship was observed between
enrichment of dysregulated genes and the frequency of the six
epigenetic switches in normal and cancer cells. The most frequent
switches were associated with the lowest enrichment of up- or
downregulated genes between the two cells. The least frequent
switches have the highest enrichment of dysregulated genes
(Figure 3D). The most frequent switches were between
H3K4me3 and H3K4&K27me3 and between H3K27me3 and
Neither. Both switches included either gain or loss of H3K27me3
Prostate Carcinogenesis
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changed gene expressions. An intermediate number of epigenetic
switches took place between H3K4me3 and Neither and between
H3K4&K27me3 and H3K27me3. Both were involved in gain or
loss of H3K4me3 (H3K4me3+/2), but affected gene expression
intermediately. The least prevalent epigenetic switches occurred
between H3K4me3 and H3K27me3, which were involved in
H3K27me3+ & H3K4me32 or H3K4me3+ & H3K27me32, but
were associated with the highest percentage of genes that changed
expression. This observation suggested that, from normal cells to
cancer cells, the most numerous epigenetic changes were either
gain or loss of H3K27me3, but this was associated with the lowest
Figure 3. Correlation of H3K4me3 or H3K27me3 Marks with Gene Expression Levels in Prostate Cells. A. Expression levels of genes with
different epigenetic marks. The expression levels of individual genes were plotted (left). Percentages of expressed genes in each category are shown
(right) with the threshold of mRNA expression set to 7 in J-Express. B. Enrichment of up- or downregulated genes in PC3 compared with EP156T cells
within epigenetically repressed, activated and unchanged groups. C. Enrichment of up- (left) or downregulated (right) genes in PC3 compared with
EP156T cells in different epigenetic changes. Blue means epigenetically activated and red means epigenetically repressed changes from EP156T to
PC3. D. The frequency of epigenetic switches as indicated from EP156T cells to PC3 cells (arrow) shown below and the corresponding enrichment of
dysregulated genes in PC3 compared with EP156T cells shown above. Asterisks indicate that switches between Neither and bivalent K4K27me3 were
omitted because of too few overlapping genes and low enrichment of dysregulated genes. E. Schematic model to show inverse relationship between
the frequency of different combinations of epigenetic switches in primary and cancer cells and the enrichment of dysregulated genes in the different
categories of epigenetic changes as depicted graphically in D.
doi:10.1371/journal.pone.0004687.g003
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switches occurred between H3K4me3 and H3K27me3 but most
frequently resulted in gene expression changes (Figure 3E). The
interpretation is that the epigenetic marks under study are strongly
linked to gene expression changes, but gain or loss of one single
marker is usually not sufficient for transcriptional changes. Instead,
combinations of changed epigenetic marks, which occur less
frequently than changes of single marks, seem necessary in order
to achieve threshold values that lead to efficient silencing or
activation of genes, possibly by precipitating cascade reactions.
Genes with Different Epigenetic Modification Patterns
were Associated with Distinct Biological Functions
Gene ontology analysis of genes with different epigenetic
modification patterns showed distinct biological functions in
EP156T and PC3. Most interestingly, the top 5 enriched terms
of H3K4me3 only, H3K4H27me3 and Neither groups in both cell
lines were exactly the same. As shown in Figure 4A, B, C most of
the enriched genes associated with H3K4me3 only were involved
in cellular metabolic process, suggesting that genes necessary to
cell basic physical functions were active in both cell lines, while
genes with neither modification showed very low enrichment
values and rather were involved in cell response functions. It is
notable that genes with the bivalent H3K4&K27me3 modification
were highly related to developmental functions in both cell lines,
and the bivalent H3K4&K27me3 group contained the highest
fraction of different genes when primary and cancer cells were
compared (Figure 2D). Concerning genes associated with
H3K27me3 only, the most enriched terms in PC3 cells were
involved in developmental functions (Figure 4D), while this was
not the case in EP156T cells (Figure 4E), suggesting that more
repressed genes in PC3 cells were developmental genes.
Comparing the gene ontology of the epigenetically activated
genes and repressed genes in PC3 cells versus EP156T cells, we
found that both gene groups were highly associated with
development and cell differentiation, suggesting that prostate
carcinogenesis is a developmental related process that is involved
in activating a set of developmental genes and silencing another set
of developmental genes (Figure 4F). Actually, there were many
known regulators in both activated and repressed groups, such as
the SOX and FOX gene families in the repressed group, and cyclin-
dependent kinase inhibitor 1B (p27/Kip1/CDKN1B) and EZH2 in
the activated group (Table S9).
Coordinated Epigenetic Switches were Very Consistent
with Gene Expression Switches of Clustered Genes
There were gene modules of particular relevance for cancer
among the activated and repressed groups. Desmosomes are
intercellular junctions that tightly link adjacent cells. Downregu-
lation of desmosomal genes is associated with epithelial to
mesenchymal transition [20] and loss of desmosomal adhesion is
implicated in the conversion of early stage tumors to invasive
cancers [21]. The desmocollin subfamily (DSC1, DSC2 and DSC3)
and desmoglein subfamily (DSG1, DSG2, DSG3 and DSG4) are
main components of desmosomes and all of them are arranged in
clusters in chr16q21. Very strikingly, promoters of all these
members exhibited epigenetic repression (H3K27me3+ and/or
H3K4me32) in PC3 cells compared with EP156T cells
(Figure 5A). Comparing gene expression data of both cell lines,
we found that H3K27me3 and H3K4me3 switches are strongly
associated with the expression switches of these genes from
EP156T cells to PC3 cells. Plakophilin (PKP) proteins localize to
cell desmosomes and nuclei, and may be involved in molecular
recruitment and stabilization during desmosome formation. There
are 4 genes of the PKP family (PKP1–4 in Chr 1, 12, 11 and 2,
respectively). All of them belonged to the repressive group and
their mRNAs were downregulated in PC3 cells (Table S9, S10).
Other repressed desmosome components included desmoplakin
Figure 4. Gene Ontology (GO) Analysis of Genes Associated with Different Histone Modification Patterns. The y axis shows the GO
term. The x axis shows the p-value concerning significant enrichment of the top 5 GO terms.
doi:10.1371/journal.pone.0004687.g004
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PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4687Figure 5. Epigenetic Switches and Decreased Expression of Gene Clusters or Gene Family. A. The DSC subfamily and DSG subfamilies
were located in clusters in chr16q21. In EP156T cells, all these genes were low in H3K27me3 and four of them were high in H3K4me3, which was
consistent with the high mRNA expression levels of only these high H3K4me3 marked genes. In PC3 cells, all these genes were high in H3K27me3 and
low in H3K4me3 modifications, which was consistent with the low mRNA expression levels of all of them. B. Seven members of the GJB family are
distributed among four different chromosomes: GJB1 in ChrX, GJB2 and GJB6 in Chr13, GJB3, 4 and 5 in Chr1, GJB7 in Chr6. In Chr13, GJA3 was located
upstream of GJB2, in Chr1 GJA4 was located downstream of GJB4. Most of the genes contained high H3K4me3 in EP156T cells with high mRNA
expression levels, while most of them contained high H3K27me3 in PC3 cells with repressed gene expression. C. There are 10 members of the
SERPINB family localized together at 18q21. The mRNA expression values represent the average6SD of three independent triplicate microarray data.
doi:10.1371/journal.pone.0004687.g005
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anchors intermediate filaments to desmosomal plaques, and PERP,
a critical component of the desmosome [22], which also exhibited
high expression in EP156T cells and silencing in PC3 cells (Table
S9, S10). The gap junction is another kind of cell junction that
allows the transport of ions and metabolites between the cytoplasm
of adjacent cells. It is formed by gap junction proteins including
the alpha (GJA) and beta (GJB) families. There are seven members
of the GJB family located in four chromosomes. We found that all
members of the GJB family belonged to the repressed group in
PC3 cells (Figure 5B). Microarray data showed that the repression
of all these gap junction genes were highly consistent with their
H3K4me3 and H3K27me3 modification patterns. This suggests
that the H3K4me3 and H3K27me3 modifications were coordi-
nated not only physically, but also functionally.
Serine proteinase inhibitors (SERPINs) are a superfamily with
diverse functions, and are involved in a number of fundamental
biological processes such as fibrinolysis, angiogenesis, programmed
cell death, development and tumor suppression [23]. Genes
encoding class B (SERPINBs) are clustered in two chromosomal
regions, 18q21 and 6q25. However, all of the SERPINB genes that
appear to be involved in cancer etiology localize together to 18q21
[24]. Based on gene expression microarray data of EP156T cells
and PC3 cells, we found that all SERPINBs in 18q21 were silenced
in PC3 cells, while 7 out of 10 were highly expressed in EP156T
cells. Analysis of the H3K4me3/H3K27me3 modifications of
SERPINBs in 18q21 in EP156T and PC3 cells showed that almost
all SERPINBs were strongly marked with H3K27me3 only in PC3
cells, while all of them contained low H3K27me3 and 7 of them
contained high H3K4me3 in EP156T cells. Very strikingly, the
seven genes with high H3K4me3 corresponded exactly to the
genes with high expression in EP156T cells (Figure 5C). It will be
attractive to verify if carcinogenesis of prostate cancer cells were
due to such coordinated epigenetic switches of these SERPINB
genes, since some of them are known tumor suppressor genes, such
as SERPINB2 and SERPINB5, and can contribute to decreased
tumor growth and metastasis [25,26].
H3K4me3 and H3K27me3 switches in HOX gene clusters
in prostate cancer cells
Homeobox (HOX) transcription factors confer anterior-poste-
rior (AP) axial coordinates to vertebrate embryos. These master
regulators of development continue to be expressed throughout
adulthood in various tissues and organs. Dysregulated expression
of homeobox genes has been described in many solid tumors and
derivative cell lines [27]. Overexpression of HOXC4,H OXC5,
HOXC6 and HOXC8 was also reported to accompany the
malignant phenotype in human prostate cells [28].
Comparing the H3K4me3 and H3K27me3 modification
patterns in HOX gene clusters in EP156T and PC3 cells, we
found that all these gene clusters were highly marked in both cells
(Figure 6). Very interestingly, most of the HOXA genes contained
high H3K4me3 and low H3K27me3 in primary prostate EP156T
cells, while they contained high H3K27me3 and low H3K4me3 in
prostate cancer PC3 cells (Figure 6A). In contrast, most genes in
the HOXC clusters contained high H3K27me3/low H3K4me3 in
EP156T cells and high H3K4me3/low H3K27me3 in PC3 cells.
The expression levels of HOXA genes and HOXC genes in EP156T
and PC3 cells showed high consistency regarding their
H3K27me3/H3K4me3 patterns in both cell lines: most HOXA
genes were much lower expressed while most of HOXC genes were
much higher expressed in PC3 cells compared with EP156T cells
(Figure 6A and B). Similar switches were also found in HOXB and
HOXD clusters: most HOXB genes were marked with H3K4me3
alone or bivalent H3K4&K27me3 in EP156T cells, while marked
by H3K27me3 alone in PC3 cells. Most of HOXD genes were
H3K27me3 only in EP156T cells but bivalent H3K4/27me3 or
H3K4me3 only in PC3 cells. The different epigenetic patterns
were also consistent with their different mRNA expression levels in
EP156T cells and PC3 cells (Figure 6C and D). The epigenetic
switches and gene expression switches of HOX cluster genes in
prostate cancer cells were most interesting, because HOX genes
were identified as classic modification targets of the polycomb
complex during development. All four clusters were highly
enriched in H3K27me3 marks and maintained expression
silencing in ES cells [13]. During development, HOX gene
products act in a combinatorial and partly redundant manner to
specify the identities of developing vertebrae [29,30]. We found
that HOXA and HOXB cluster genes were epigenetically repressed
and transcriptionally silenced from normal cells to cancer cells
while HOXC and HOXD cluster genes exhibited inverse switches at
both epigenetic and transcriptional levels, suggesting distinct and
may be inverse biological functions during prostate carcinogenesis.
H3K4me3/H3K27me3 modification of miRNA genes in
prostate cells
MicroRNAs (miRNAs) are small, endogenously expressed
noncoding RNAs that regulate the expression of protein-coding
genes. Increasing evidence supports miRNAs as key participants in
gene regulatory networks [31]. miRNAs might function biologically
as either oncogenes or tumor suppressor genes and are involved in
cancer pathogenesis. A number of studies have detected frequent
alterations of miRNA expression in a variety of human malignancies
including prostate cancer [32,33,34,35]. Epigenetic regulation of
miRNA expression in cancer was addressed by treating cancer cell
lines with DNA-methylation inhibitors or HDAC inhibitors [36,37].
These data suggest that epigenetic changes play critical roles in
miRNA expression in human cancers.
Using ChIP-chipanalysis, we have achieved genome-wide profiles
of the trimethylation of H3K4 and H3K27 in promoters of human
miRNAs in both prostate primary and cancer cells. Altogether, we
found that 76 miRNAs gained H3K4me3 and/or lost H3K27me3;
and 114miRNAs gained H3K27me3 and/or lostH3K4me3 inPC3
cells compared with EP156T cells, suggesting that these miRNAs
wereepigeneticallyactivatedandrepressedinPC3cells,respectively.
To confirm that these epigenetic switches were associated with
differential miRNA transcription in prostate cells, miRNA expres-
sion microarrays were performed in both EP156T cells and PC3
cells. The comparison showed that 28 miRNAs were upregulated
and 30 downregulated in PC3 cells compared to EP156T cells
(Table S11, Figure 7A). Matching the lists of epigenetically activated
and repressed miRNA genes according to the ChIP-chip data with
the differentially expressed miRNAs in EP156T and PC3 cells, we
found that up to 33% of the upregulated and 57% of the
downregulated miRNAs in PC3 cells overlapped correspondingly
(Figure 7A, B), thus revealing a highly consistent pattern of
H3K4me3/H3K27me3 modifications coupled with miRNA ex-
pression in prostate cancer (Chi-square test, p,0.01). Among these
miRNAs, some are highly relevant in cancer, such as miR-205 and
miR-200b, which were H3K4me3 marked in EP156T cells and
H3K27me3 marked in PC3 cells (Figure 7B), and have been
reported as suppressors of the transcription factors ZEB1 and SIP1
[38,39].DownregulationofthesemiRNAsmaybeanimportantstep
in tumor progression. It is very likely that the epigenetic switch from
H3K4me3 to H3K27me3 may be involved in decreased expression
of miR-205 and miR-200b, thus increasing the metastatic ability of
PC3 cells, a cell line isolated from a bone metastasis of a prostatic
adenocarcinoma.
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PLoS ONE | www.plosone.org 8 March 2009 | Volume 4 | Issue 3 | e4687Figure 6. Epigenetic Switches and Expression Changes of HOX Cluster Genes. HOX genes located in 4 clusters, HOXA (A), HOXB (B), HOXC (C)
and HOXD (D), in chromosome 7, 17, 12 and 2 of the human genome, respectively. The mRNA expression values represent the average6SD of three
independent triplicate microarray data.
doi:10.1371/journal.pone.0004687.g006
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PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4687Activated Oncogenes and Repressed Tumor Suppressor
Genes in PC3 cells Indicate an H3K4me3/H3K27me3
Signature in Prostate Carcinogenesis
In cancer cells, activation of oncogenes and inactivation of tumor
suppressors represent critical steps at every stage of tumorigenesis.
Based on the integration of epigenomic and genomic analysis of
prostate cancer and primary cells, we have identified 527
upregulated genes with activated epigenetic modification and 668
downregulated genes with repressed epigenetic modification in PC3
cells. Many activated genes are known oncogenes and the repressed
genes are tumor suppressor genes (Figure 8, Table S12). Oncogenes
and tumor suppressor genes were separated into those previously
published to play a role during carcinogenesis (Figure 8A) and those
who play a role in progression of established tumors (Figure 8B).
Some of these genes have known functions in prostate cancer, such
as FGFR1, BCL2, HOXC5, HOXA4, TWIST1, EZH2, KLF4, CTGF
(Table S12). For most of them this is the first report, to our
knowledge, that their dysregulated expression in cancer may be
connected to H3K4me3 and H3K27me3 switches. Our present
results provide a novel view to understanding the coordinated
upregulation of these oncogenes and repression of these tumor
suppressor genes in carcinogenesis, thus underscoring the
H3K4me3/H3K27me3 signature in prostate carcinogenesis.
Discussion
This work has integrated microarray-based global gene
expression and epigenomic profiling of prostate cancer cells
and their normal counterparts and found that transcriptional
activating marks (gain of H3K4me3 or loss of H3K27me3) and
Figure 7. Dysregulated miRNA expression in PC3 Cells and corresponding patterns of H3K4me3 and H3K27me3 modifications.
miRNA genes displayed consistent changes in both expression levels (left) and epigenetic differences (right) between EP156T and PC3 cells.
doi:10.1371/journal.pone.0004687.g007
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tightly associated with upregulated and downregulated genes in
prostate cancer cells, respectively. The most prevalent switches
were gain or loss of H3K27me3 coupled with the lowest
enrichment of differentially expressed genes. The least prevalent
switches were the ones between H3K4me3 and H3K27me3, but
this was coupled with the highest enrichment of dysregulated
genes, suggesting that the epigenetic marks under study are
strongly linked to gene expression changes, but gain or loss of
one single marker is usually not sufficient for transcriptional
changes. Instead, combinations of changed epigenetic marks,
which occur less frequently than changes of single marks, seem
necessary in order to achieve threshold values that lead to
efficient silencing or activation of genes. Furthermore, we found
that mRNA expression of entire functional modules of genes is
coordinated at this epigenetic level. Finally, we identified a set of
overexpressed oncogenes with activated epigenetic marks and
underexpressed tumor suppressor genes with repressed epige-
netic marks in prostate cancer cells, indicating a strong
epigenetic signature in prostate carcinogenesis. To our knowl-
edge, this is the first report of genome-wide profiling of the
activation marks H3K4me3 and the silencing mark H3K27me3
in both cancer cells and primary cells, and sheds light on the
understanding of dynamic epigenetic changes during carcino-
genesis.
The bivalent H3K4&K27me3 modification was first observed
and proposed to be specific in ES cells [12]. Further work revealed
that it was also present in differentiated cells such as T cells and
MEFs [16,17,18]. Our data show that it also can be found in both
prostate primary and cancer cells. However, the bivalent
H3K4&K27me3 seems quite different between ES cells and
somatic cells. Firstly, the percentage of H3K27me3 marks
colocalizing with H3K4me3 was extremely high (both were
89%) in ES cells [13,19], but considerably lower in EP156T and
PC3 cells (around 50%). A similar percentage was observed in T
cells (59%) [18]. Secondly, the mRNA expression of bivalently
H3K4&K27me3 marked genes was very low in ES cells, with only
slightly higher expression levels than H3K27me3 only marked
genes [13,17,19]. In contrast, we found that bivalent
H3K4&K27me3 marked genes were rather active and only
moderately less expressed than H3K4me3 only marked genes in
both EP156T and PC3 cells. Again, a similar activity of bivalent
H3K4&K27me3 marked genes were observed in T cells, in which
the percentages of expressed genes were 76%, 59% and 27%
Figure 8. Epigenetic Signature in Prostate Cancer. A set of well defined carcinogenesis related genes (A) and metastasis related genes showed
consistent epigenetic switches and gene expression changes from prostate primary (EP156T) to cancer cells (PC3).
doi:10.1371/journal.pone.0004687.g008
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H3K27me3 only, respectively.
Very recently, global epigenetic silencing marks in PC3 cells
were reported by two groups, and both found that H3K27me3
modified loci excluded DNA hypermethylation [5,11]. Most
interestingly, the increased and decreased DNA methylation
regions in HOX gene clusters identified by Gal-Yam et al.
correlated very well with the switched H3K4me3/H3K27me3
regions between EP156T and PC3 cells. The decreased DNA
methylation changes of the HOXB4–B6 region, which suggested
high H3K27me3 modification at these loci, exhibited high
H3K27me3/low H3K4me3 in PC3 cells of our study. In the
HOXC cluster the other study found increased DNA methylation
changes, which suggested none or low H3K27me3 modification at
this locus, again supporting our findings of very low H3K27me3 in
the whole cluster and high H3K4me3 in the N terminal part of
this cluster in PC3 cells. It will be attractive to achieve whole
genome mapping of combined DNA methylation, H3K27me3
and H3K4me3 marks in both malignant and normal cells to get an
even more detailed insight into epigenetic switches during
carcinogenesis. Coordinated community based efforts to decode
the human epigenome are planned [40]. The emerging picture is
that functional groups of genes shift their gene expression patterns
during carcinogenesis in association with specific combinations of
epigenetic modifications. The cascade nature of epigenetic
regulation may cause individual epigenetic modifications to be
somewhat redundant as markers of the epigenetic state, and this
might facilitate an overall understanding of coordinated regulation
of gene expression in cancer and facilitate identification of
molecular targets of cancer therapy.
Materials and Methods
Cell lines, Antibodies and Reagents
The PC3 prostate cancer cell line was obtained from the
American Type Culture Collection (ATCC, Rockwell, MD, USA).
The EP156T primary prostate epithelial cells have been described
[10]. Antibodies against H3K4me3 and H3K27me3 were bought
from Abcam. Reagents for real-time qPCR were from Applied
Biosystems, Foster City, USA.
Global Gene Expression Analysis
The Agilent Human Whole Genome (4644 k) Oligo Micro-
array with Sure Print Technology (Agilent Technologies, Palo
Alto, CA, USA) was used to analyze samples in the present study.
Quality and yields of total RNA were assessed using the Agilent
2100 Bioanalyzer (Agilent Tech), 1% agarose gel ethidium
bromide electrophoresis and Powerwave spectrophotometry at
260 nm and 280 nm. One mg of DNAse-treated total RNA was
converted into cDNA and Cy3-labeled cRNA using the Low RNA
Input Linear Amplification Kit PLUS, One-Color kit (Agilent
Tech.) according to instructions. We used gmeansignals, i.e. signals
without background subtraction. Intraarray normalization of dye
effects was carried out using quantile normalization [42] and genes
with more than 25% missing values were removed. The
normalized channel values were log(2) transformed and combined
into a gene expression data matrix. Data were formatted in a J-
Express-file suitable for additional data mining (http://www.
molmine.com/) [43]). Following normalisation, analysis of vari-
ance (ANOVA) of the J-Express program package was used for
identification of differentially expressed genes. Only genes that
changed more than 1.2 fold and with p-values,0.005 were
considered as differentially expressed genes between the prostate
benign and cancer groups, and only genes that changed more than
2.0 fold with p-values,0.01 were considered as differentially
expressed genes in cell lines.
miRNA Microarray Analysis
The global miRNA expression of each sample was measured in
triplicates using the Febit Genome One technology (Febit Biomed
GmbH, Heidelberg, Germany). Each microarray contains the
reverse complement of 866 miRNAs and mature star sequences as
published in the Sanger mirBase 12.0. Seven replicates of these
probes were synthesized in random order on the array together
with control probes. Total RNA was purified using the miRNeasy
Mini kit (Qiagen), the quality control was done with the Agilent
Bioanalyzer 2100, using the RNA 6000 nano kit (Agilent). For
each array 1.5 mg total RNA was labeled using the mirVANA
TM
miRNA labeling kit (Ambion) following the manufacturer’s
instructions. Then, samples were hybridized for 16 hours at
42uC on the biochip. During the incubation, samples were slightly
moved using Argon pressure. The washing and signal amplifica-
tion passed according to Febit’s standard procedures and criteria.
Signal intensities were measured by autoexposure time using a
CCD camera. Raw data were further processed by the statistical
programming framework R: A background correction was done.
The intraarray replicates were merged by computing their mean
intensity. Standard quantile normalization was applied to account
for interarray effects. Finally, probes that did not show expression
(normalized intensity below 500) were removed. To detect probes
with significant differential expression, moderate t-statistics were
calculated and the respective p-values were adjusted for multiple
testing using Benjamin-Hochberg correction.
Chromatin Immunoprecipitation on DNA Microarrays
(ChIP-chip)
ChIP-chip was performed according to the Agilent ChIP-chip
protocol with modifications. To immunoprecipitate chromatin,
6610
7 cells were treated with 1% formaldehyde at room
temperature for 10 min followed by quenching with 0.125 M
glycine. Cells were lysed and the nuclei were sonicated under
conditions yielding fragments ranging from 200 bp to 800 bp. Five
per cent of the sonicated material was saved as whole-cell extract.
Sonicated lysate was divided to three equal volumes and
immunoprecipitated with specific or negative antibody bound to
protein A magnetic beads (Invitrogen) overnight at 4uC with
rocking. Antibodies used were against: H3K4me3 (Abcam
no. ab8580) or H3K27me3 (Abcam no. ab6002) or mouse IgG
(Sigma). Five mg of antibody was used per 2610
7cells. Immuno-
precipitated complexes were collected, washed and eluted using
Dynal Magnetic Particle Concentrator (Invitrogen). Eluted DNA
and whole-cell extracts were incubated at 65uC in a rotating
incubator for 8 hours to reverse crosslinks. DNA samples were
sequentially treated with RNase A and proteinase K and then
purified by phenol/chloroform extraction. The purified DNA was
ethanol precipitated using glycogen as a carrier and resuspended
in PCR-grade water. For each microarray, 2 mg ChIPed DNA was
labeled using the CGH kit (Invitrogen) and Cy3-dUTP or Cy5-
dUTP (Amersham). Human G4489A 26244 K promoter arrays
(Agilent) were hybridized for 40 h at 65uC and subsequently
scanned using an Agilent Scanner controlled by Agilent Scan
Control 7.0 software. Raw image files were extracted with Agilent
Feature Extraction 9.1 software. H3K4me3 or H3K27me3
enriched genes were analyzed using Agilent’s ChIP Analytics 1.3
software, incorporating the Whitehead Error Model, which has a
false-positive rate of approximately 0.5% and a false-negative rate
of approximately 20%. Probes that were associated with modified
histones were called on the basis of a neighbourhood p-value of
Prostate Carcinogenesis
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human genome (HG17, May 2004).
ChIP-PCR
Real-time quantitative PCR was done to verify the ChIP-chip
data. Taqman primers (Table S13) were designed to detect the
promoter region (25.5 Kb upstream and +2.5 Kb downstream of
TSS). 10 ng ChIPed DNA and input DNA were used for
amplification, the enrichment of ChIPed DNA was calculated
based on the DCt value, 3.5 DCt equals 10 fold of the amount of
target DNA. Three biological and technical replicates were done
for each sample.
BASE database, ArrayExpress and Microarray Accession
Numbers
Annotated microarray data were uploaded in the BASE
database (http://www.cbu.uib.no), formatted and exported to
ArrayExpress at the European Bioinformatics Institute (http://
www.ebi.ac.uk/microarray/) according to MIAME guidelines
(Gene Expression study ArrayExpress accession number: E-
TABM-634; Histone Methylation pattern ChIP-chip study
ArrayExpress accession number: E-TABM-635).
Gene Ontology Analysis
Gene ontology was performed using DAVID Bioinformatics
Resources (http://david.abcc.ncifcrf.gov/).
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